CCT5 maintains mitotic fidelity and promotes early colorectal tumorigenesis.
Colorectal cancer (CRC) is a leading cause of cancer-related mortality, and early tumorigenesis is closely associated with mitotic dysregulation and chromosomal instability.
APA
Ji M, Zhuang W, et al. (2026). CCT5 maintains mitotic fidelity and promotes early colorectal tumorigenesis.. iScience, 29(4), 115223. https://doi.org/10.1016/j.isci.2026.115223
MLA
Ji M, et al.. "CCT5 maintains mitotic fidelity and promotes early colorectal tumorigenesis.." iScience, vol. 29, no. 4, 2026, pp. 115223.
PMID
41890968
Abstract
Colorectal cancer (CRC) is a leading cause of cancer-related mortality, and early tumorigenesis is closely associated with mitotic dysregulation and chromosomal instability. To define molecular mechanisms supporting mitotic fidelity during CRC initiation, we combined multi-omics profiling, genetically engineered mouse models, and functional assays to examine the role of the chaperonin subunit CCT5. Transcriptomic and proteomic analyses revealed elevated CCT5 expression in stage I CRC and precancerous lesions, indicating diagnostic relevance. The genetic depletion of CCT5 suppressed epithelial proliferation, reduced dysplastic transformation, and limited tumor initiation . In CRC cells, CCT5 silencing impaired proliferation and induced G2/M arrest. Mechanistically, CCT5 interacts with CDC20 and facilitates turnover of the MCC-CDC20-APC/C complex, enabling metaphase-to-anaphase progression. These findings position CCT5 as a regulator of early CRC development with implications for early detection and therapeutic intervention.
같은 제1저자의 인용 많은 논문 (4)
- A Macrophage-Driven Multimodal Nanoplatform Conquers Ovarian Cancer Peritoneal Metastasis.
- A novel rhein derivative Y01 inhibits hepatocellular carcinoma by inducing apoptosis through regulating PI3K/AKT/mTOR pathway.
- BI-749327 inhibits the proliferation of hepatocellular carcinoma by targeting the TRPC6 channel.
- Construction of a predictive model based on the risk of relapse after cytarabine consolidation therapy in acute myeloid leukemia patients.